Ripertamab for frequent relapses in nephrotic syndrome
Treatments studied
Part of Kidney & urinary clinical trials.
This trial tests a new medicine called ripertamab for children and young adults with nephrotic syndrome that keeps coming back or requires steroids. The goal is to see if it helps prevent relapses with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years old or older
- Your nephrotic syndrome is currently in complete remission (very low protein in urine)
- In the past 2 months, you have not taken certain immune-suppressing medications like cyclophosphamide, cyclosporine, or mycophenolate mofetil
- In the past 6 months, you have not received certain CD20 antibody treatments (other than rituximab)
- Your kidney function is good (eGFR above 60)
- You have no other causes for your kidney disease (like lupus or cancer) and no active infections like TB, HIV, or hepatitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Ripertamab for people with neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the optic nerves and spinal cord. The drug aims to reduce relapses (flare-ups) of symptoms. It may be an option if you've had recent relapses despite current treatment.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
This trial tests a new medicine called zuberitamab for children who have just had their first episode of nephrotic syndrome and have responded well to steroids. The goal is to see if this medicine can help keep the disease from coming back, with fewer side effects than standard treatments.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial tests an investigational drug called Ripertamab for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition causing weakness and numbness. The goal is to see if the drug can improve symptoms compared to no additional treatment.
Hear when a new FRNS/SDNS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.